14.91
-0.49 (-3.21%)
| Previous Close | 15.41 |
| Open | 15.27 |
| Volume | 1,364,350 |
| Avg. Volume (3M) | 1,291,045 |
| Market Cap | 1,011,923,776 |
| Price / Earnings (TTM) | 6.63 |
| Price / Earnings (Forward) | 7.72 |
| Price / Sales | 2.78 |
| Price / Book | 1.56 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 |
| Profit Margin | 45.91% |
| Operating Margin (TTM) | 28.48% |
| Diluted EPS (TTM) | 2.25 |
| Quarterly Revenue Growth (YOY) | -22.80% |
| Quarterly Earnings Growth (YOY) | 50.00% |
| Total Debt/Equity (MRQ) | 1.11% |
| Current Ratio (MRQ) | 10.23 |
| Operating Cash Flow (TTM) | 132.66 M |
| Levered Free Cash Flow (TTM) | 78.31 M |
| Return on Assets (TTM) | 8.53% |
| Return on Equity (TTM) | 24.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | InMode Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -4.0 |
| Average | 1.25 |
|
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 14.29% |
| % Held by Institutions | 67.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Meitav Investment House Ltd | 31 Dec 2024 | 1,334,405 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (Barclays, 60.97%) | Buy |
| Median | 15.63 (4.83%) | |
| Low | 15.00 (Canaccord Genuity, 0.60%) | Hold |
| 15.00 (Jefferies, 0.60%) | Hold | |
| Average | 17.56 (17.77%) | |
| Total | 1 Buy, 3 Hold | |
| Avg. Price @ Call | 14.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 30 Apr 2025 | 24.00 (60.97%) | Buy | 14.26 |
| 05 Feb 2025 | 29.00 (94.50%) | Buy | 17.96 | |
| Canaccord Genuity | 29 Apr 2025 | 15.00 (0.60%) | Hold | 14.26 |
| UBS | 29 Apr 2025 | 16.25 (8.99%) | Hold | 14.26 |
| Jefferies | 14 Apr 2025 | 15.00 (0.60%) | Hold | 15.08 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |